Michelle Gilson
Stock Analyst at Morgan Stanley
(1.10)
# 3,755
Out of 4,966 analysts
31
Total ratings
32.14%
Success rate
-7.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $4.94 | +304.86% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $69.72 | -56.97% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $7.12 | +138.76% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $194.27 | +0.89% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $17.50 | +157.14% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $19.76 | +284.62% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $58.27 | +56.17% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $4.94
Upside: +304.86%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $69.72
Upside: -56.97%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $7.12
Upside: +138.76%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $194.27
Upside: +0.89%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $17.50
Upside: +157.14%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $19.76
Upside: +284.62%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $58.27
Upside: +56.17%